Literature DB >> 23800448

Long-term safety of abatacept in patients with rheumatoid arthritis.

Fabiola Atzeni1, Piercarlo Sarzi-Puttini, Alessandra Mutti, Serena Bugatti, Lorenzo Cavagna, Roberto Caporali.   

Abstract

Abatacept is a selective T cell co-stimulation modulator that was first approved by the Italian Medicines Agency and reimbursed by the Italian National Health Service when used to treat active rheumatoid arthritis "not sufficiently responsive to other disease-modifying anti-rheumatic drugs (DMARDs) including at least one TNF inhibitor", and is now also approved as a first line biological agent. The aim of this review is to summarise the safety data collected in clinical trials and observational studies.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Abatacept; Rheumatoid arthritis; Safety

Mesh：

Substances：

Year:  2013        PMID： 23800448     DOI： 10.1016/j.autrev.2013.06.011

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN： 1568-9972            Impact factor:   9.754


  14 in total

Review 1.  Stem cell therapy in autoimmune rheumatic diseases: a comprehensive review.

Authors:  Bin Liu; ShangAn Shu; Thomas P Kenny; Christopher Chang; Patrick S C Leung
Journal:  Clin Rev Allergy Immunol       Date:  2014-10       Impact factor: 8.667

2.  Memory B Cells and Response to Abatacept in Rheumatoid Arthritis.

Authors:  Pierre Gazeau; Guillermo Carvajal Alegria; Valérie Devauchelle-Pensec; Christophe Jamin; Julie Lemerle; Boutahar Bendaoud; Wesley H Brooks; Alain Saraux; Divi Cornec; Yves Renaudineau
Journal:  Clin Rev Allergy Immunol       Date:  2017-10       Impact factor: 8.667

Review 3.  Autoimmunity in 2013.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2014-08       Impact factor: 8.667

4.  Unique topics and issues in rheumatology and clinical immunology.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2014-08       Impact factor: 8.667

Review 5.  CTLA4-Ig in B7-1-positive diabetic and non-diabetic kidney disease.

Authors:  Roberto Bassi; Alessia Fornoni; Alessandro Doria; Paolo Fiorina
Journal:  Diabetologia       Date:  2015-09-26       Impact factor: 10.122

6.  Attenuation of Collagen-Induced Arthritis in rat by nicotinic alpha7 receptor partial agonist GTS-21.

Authors:  Yiping Hu; Ruoxi Liu; Jinchao Li; Ye Yue; Wenxiang Cheng; Peng Zhang
Journal:  Biomed Res Int       Date:  2014-02-27       Impact factor: 3.411

Review 7.  Advances in the treatment of rheumatoid arthritis.

Authors:  Nancy Vivar; Ronald F Van Vollenhoven
Journal:  F1000Prime Rep       Date:  2014-05-06

8.  Targeting of the CD80/86 proinflammatory axis as a therapeutic strategy to prevent severe COVID-19.

Authors:  Antonio Julià; Irene Bonafonte-Pardàs; Antonio Gómez; María López-Lasanta; Mireia López-Corbeto; Sergio H Martínez-Mateu; Jordi Lladós; Iván Rodríguez-Nunez; Richard M Myers; Sara Marsal
Journal:  Sci Rep       Date:  2021-06-01       Impact factor: 4.379

Review 9.  Treatment comparison in rheumatoid arthritis: head-to-head trials and innovative study designs.

Authors:  Ennio Giulio Favalli; Serena Bugatti; Martina Biggioggero; Roberto Caporali
Journal:  Biomed Res Int       Date:  2014-04-16       Impact factor: 3.411

10.  A 52-week, open-label study evaluating the safety and efficacy of tabalumab, an anti-B-cell-activating factor monoclonal antibody, for rheumatoid arthritis.

Authors:  Maria Greenwald; Leszek Szczepanski; Alastair Kennedy; Melissa Veenhuizen; Wendy J Komocsar; Emery Polasek; Kelly Guerrettaz; Pierre-Yves Berclaz; Chin Lee
Journal:  Arthritis Res Ther       Date:  2014-08-29       Impact factor: 5.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.